Because shikonin treatment could efficiently block the nuclear translocation of PKM2, we assessed transcriptome-wide effects of shikonin treatment on AD and control iNs (n = 8 shikonin-treated AD iNs, n = 8 vehicle-treated AD iNs, and n = 3 untreated control iNs). Here, PKM is linked to Alzheimer disease.